Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 101–200 of 1,001
Gawrieh, S., Vilar-Gomez, E., Wilson, L. A., Pike, F., Kleiner, D. E., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Kowdley, K. V., Hameed, B., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.008 · Cited by 94
Self-citationLe, M. H., Le, D. M., Baez, T. C., Dang, H., Nguyen, V. H., Lee, K., Stave, C. D., Ito, T., Wu, Y., Yeo, Y. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0485 · Cited by 103
Kendall, T. J., Jimenez-Ramos, M., Turner, F., Ramachandran, P., Minnier, J., McColgan, M. D., Alam, M., Ellis, H., Dunbar, D. R., Kohnen, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02602-2 · Cited by 92
“Indeed, patient characteristics (higher age and body mass index (BMI)), more frequent comorbidities and baseline disease severity likely explain the higher incidence of outcomes in SteatoSITE compared with other published MASLD cohorts 11,61,62 .”
BackgroundResultInfluentialLe, P. N. B., Payne, J. Y., Zhang, L., Deshpande, A., Rothberg, M. B., Alkhouri, N., Herman, W. H., Hernández, A. V., Schleicher, M. C., Ye, W., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.07.033 · Cited by 102
Self-citationNoureddin, M., Truong, E., Mayo, R., Martínez‐Arranz, I., Mincholé, I., Bañales, J. M., Arrese, M. A., Cusi, K. J., Arias, M., Brůha, R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000542 · Cited by 97
“[5,6] Thus, clinical trials, especially phase 3 registry trials, have focused on MASH with ≥ F2, also known as “ at-risk MASH.”
BackgroundSelf-citationNoureddin, M., Frías, J. P., Neff, G. W., Lucas, K. J., Behling, C. A., Bédossa, P., Dubourg, J., Chan, D. C., Burch, M., Fong, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01073-6 · Cited by 107
Self-citationHadjihambi, A., Konstantinou, C., Klohs, J., Monsorno, K., Guennec, A. D. L., Donnelly, C., Cox, I. J., Kusumbe, A. P., Hosford, P. S., Soffientini, U., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.008 · Cited by 92
“2 Several studies have reported the negative effects of un-healthy diet and obesity on cerebral function and cognition.”
BackgroundDiabetes and cirrhosis: Current concepts on diagnosis and management
Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 93
“While pioglitazone has been incorporated into clinical practice guidelines for the treatment of NASH without cirrhosis,[11,13,99,101,103,110] there is limited data with pioglitazone in patients with cirrhosis and it must be avoided in the presence of decompensated cirrhosis (the drug is metabolized mainly by CYPC28 an…”
BackgroundInfluentialMarjot, T., Tomlinson, J. W., Hodson, L., & Ray, D. W. (2023) · Gut · doi:10.1136/gutjnl-2023-329998 · Cited by 83
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 137
Self-citationShi, H., Wang, X., Li, F., Gerlach, B. D., Yurdagul, A., Moore, M. P., Zeldin, S., Zhang, H., Cai, B., Zheng, Z., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8309 · Cited by 85
Kuchay, M. S., Martínez‐Montoro, J. I., Kaur, P., Fernández‐García, J. C., & Ramos‐Molina, B. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101696 · Cited by 93
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 152
“33 The global pooled incidence of NAFLD-related HCC was 1.25 per 1,000 person-year, increasing to 14.46 per 1,000 person-year in patients with advanced fibrosis.”
InfluentialUnderstanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0010 · Cited by 104
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 124
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
“The transition to fibrosis and cirrhosis is crucial because fibrosis is the key determinant of adverse outcomes and mortality and rates of liver-related complications increase with higher fibrosis stages.(3,8) The impact of NASH as a health burden is demonstrated by the fact that NASH is the fastest growing cause of h…”
BackgroundResultInfluentialMetALD: new opportunities to understand the role of alcohol in steatotic liver disease
Israelsen, M. E., Torp, N., Johansen, S., Thiele, M. S., & Krag, A. A. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00206-6 · Cited by 90
Du, K., Wang, L., Jun, J. H., Dutta, R. K., Maeso‐Díaz, R., Oh, S., Ko, D. C., & Diehl, A. M. (2024) · Nature Aging · doi:10.1038/s43587-024-00652-w · Cited by 93
“People with MASLD and advanced liver fibrosis are at increased risk for both degeneration of other organs and all-cause mortality 57 .”
Self-citationArcher, A. J., Belfield, K., Orr, J. G., Gordon, F. H., & Abeysekera, K. W. M. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2021-102064 · Cited by 94
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77
“12,40,41 Therefore, numerous studies have been conducted to investigate the effect of antidiabetic therapy on MASH and fibrosis, as improved histology is more likely to translate into favourable clinical outcomes in this patient cohort.”
BackgroundIsraelsen, M. E., Madsen, B. S., Torp, N., Johansen, S., Hansen, C. D., Detlefsen, S., Andersen, P., Hansen, J. K., Lindvig, K. P., Rasmussen, D. N., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00010-9 · Cited by 87
Paternostro, R., Kwanten, W. J., Hofer, B., Semmler, G., Bagdadi, A., Luzko, I., Hernández–Gea, V., Graupera, I., García‐Pagán, J. C., Saltini, D., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.033 · Cited by 87
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“The severity of fi - brosis is the most signi fi cant predictor of adverse liver outcomes (10).”
BackgroundNon-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
Eng, P. C., Forlano, R., Tan, T., Manousou, P., Dhillo, W. S., & Izzi‐Engbeaya, C. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100835 · Cited by 84
Decoding the Liver-Heart Axis in Cardiometabolic Diseases
Capone, F., Vacca, A., Bidault, G., Sarver, D. C., Kamińska, D., Strocchi, S., Vidal‐Puig, A., Greco, C. M., Lusis, A. J., & Schiattarella, G. G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325492 · Cited by 81
Deltenre, P., Zanetto, A., Saltini, D., Moreno, C., & Schepis, F. (2022) · Hepatology · doi:10.1002/hep.32596 · Cited by 73
Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy
Louissaint, J., Deutsch‐Link, S., & Tapper, E. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.036 · Cited by 78
Wong, Y. J., Zhaojin, C., Tosetti, G., Degasperi, E., Sharma, S., Agarwal, S., Liu, C., Chan, Y., Li, J., Qi, X., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0181 · Cited by 74
Tamaki, N., Ahlholm, N., Luukkonen, P. K., Porthan, K., Sharpton, S. R., Ajmera, V., Kono, Y., Dave, S., Ahmed, A., Sundaram, V., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162513 · Cited by 69
Self-citationAntifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
Self-citationIssa, G., Shang, Y., Strandberg, R., Hagström, H., & Wester, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.001 · Cited by 89
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Metabolites · doi:10.3390/metabo12121243 · Cited by 69
Manzano-Nunez, R., Santana-Dominguez, M., Rivera-Esteban, J., Sabiote, C., Sena, E., Bañares, J., Tacke, F., & Pericàs, J. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030856 · Cited by 61
“The increasing burden of non-alcoholic fatty liver disease (NAFLD), which now is estimated to affect approximately 25% of the global population [1], has become a matter of global concern as the disease comes with a higher risk of other metabolic impairments, including obesity, type 2 diabetes mellitus, and the consequ…”
BackgroundSleep Apnea, Obesity, and Diabetes — an Intertwined Trio
Kurnool, S., McCowen, K. C., Bernstein, N., & Malhotra, A. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01510-6 · Cited by 84
“NAFLD is sometimes regarded as a cardiovascular risk factor although the causal pathways are unclear and may well involve insulin resistance, obesity, and OSA at least to some extent [50].”
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 86
“However, particular interest has been focused on metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fi brosis, as these have been linked to disease progression [18] and mortality [19], respectively.”
Younossi, Z. M., Razavi, H. A., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K. J., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70020 · Cited by 78
“Moreover, the incidence of liver-related complications per 100 person-years increased with advancing fibrosis stage (F0– F2 compared to F3 vs. F4) [45].”
InfluentialSelf-citationOpportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Thiele, M. S., Villesen, I. F., Niu, L., Johansen, S., Sulek, K., Nishijima, S., Espen, L. V., Keller, M. I., Israelsen, M. E., Suvitaival, T., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.035 · Cited by 75
Implementation of a liver health check in people with type 2 diabetes
Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00270-4 · Cited by 63
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer, K., & Stauber, R. E. (2023) · Biomedicines · doi:10.3390/biomedicines11082108 · Cited by 78
“In patients with NAFLD-related cirrhosis, though, hepatic complications are the leading causes of death [25].”
BackgroundEnvisioning how to advance the MASH field
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M., & Lazarus, J. V. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00938-9 · Cited by 69
Self-citationTargeting the liver clock improves fibrosis by restoring TGF-β signaling
Crouchet, É., Dachraoui, M., Jühling, F., Roehlen, N., Oudot, M. A., Durand, S., Ponsolles, C., Gadenne, C., Heydmann, L., Moehlin, J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.034 · Cited by 73
Beta-blockers in the era of precision medicine in patients with cirrhosis
Albillos, A., & Krag, A. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.005 · Cited by 68
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 70
“NASH currently affects more than 80 million people worldwide, and the prevalence of NASH and NASH-related end-stage liver disease is projected to rise continuously over the next decade, posing a significant challenge for future public health management [69–71].”
BackgroundArmandi, A., & Bugianesi, E. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.005 · Cited by 68
“MASH and significant fibrosis (fibrosis stage equal or above 2) are associated with increased morbidity and mortality, concerning either hepatic (progression to end-stage liver disease and hepatocellular carcinoma) or non-hepatic (mostly cardiovascular) complications [2,3].”
Du, K., Umbaugh, D. S., Wang, L., Jun, J. H., Dutta, R. K., Oh, S., Ren, N., Zhang, Q., Ko, D. C., Ferreira, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57616-w · Cited by 67
“This knowledge gap has limited development of effective pharmacotherapies and hence, MASLD is driving the health and economic burden of liver disease 1,2 .”
Self-citationPuengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59
Rosso, C., Caviglia, G. P., Birolo, G., Armandi, A., Pennisi, G., Pelusi, S., Younes, R., Liguori, A., Perez-Diaz-del-Campo, N., Nicolosi, A., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.024 · Cited by 59
Tamaki, N., Kurosaki, M., Huang, D. Q., & Loomba, R. S. (2022) · Hepatology Research · doi:10.1111/hepr.13764 · Cited by 66
“However, in a study that investigated 1773 patients with biopsy‐proven NAFLD, there was no significant association between CVD incidence and liver fibrosis.(110) In another study including 458 patients with biopsy‐proven NAFLD and fibrosis stage 3 or 4, CVD incidence was higher in patients with F3 than those with F4.”
Self-citationDiabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
Circulating miRNAs associated with nonalcoholic fatty liver disease
Atic, A. I., Thiele, M. S., Munk, A., & Dalgaard, L. T. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00253.2022 · Cited by 68
D’Amico, G., Zipprich, A., Villanueva, C., Sorda, J. A., Morillas, R. M., Garcovich, M., García-Retortillo, M., Martínez, J., Calès, P., D’Amico, M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000652 · Cited by 70
“Although the development of cirrhosis seems to be much longer in NASH cirrhosis, [36] once decompensation occurs, the course appears to be similar to that of decompensated cirrhosis of other etiologies.”
BackgroundLabenz, C., Arslanow, A., Nguyen-Tat, M., Nagel, M., Wörns, M., Reichert, M., Heil, F. J., Mainz, D., Zimper, G., Römer, B., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.009 · Cited by 63
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
Koning, M., Herrema, H., Nieuwdorp, M., & Meijnikman, A. S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2226922 · Cited by 56
“It is now widely accepted that liver fibrosis as a result of liver injury secondary to NAFLD, is a major prognostic predictor for liver-related and overall morbidity and mortality.(2,3) Our understanding of the factors that determine disease progression has evolved, but we are still not able to identify those patients…”
BackgroundNon-invasive tests of non-alcoholic fatty liver disease
Li, G., Zhang, X., Lin, H., Liang, L. Y., Wong, G. L., & Wong, V. W. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002027 · Cited by 64
“532 increasing fibrosis stage in NAFLD patients.([4]) While liver biopsy remains the only accepted method to diagnose NASH and the reference standard to evaluate fibrosis, it is an invasive procedure and cannot be widely applied.”
BackgroundMetabolic Dysfunction–Associated Steatotic Liver Disease
Ali, S. M. J., & Lai, M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02933 · Cited by 66
Vine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
“108 The 4.27% prevalence of NAFLD in those with PCOS in our results is very low compared to fi ndings in other population cohort studies, which show a 40%-50% prevalence in those with PCOS.”
ResultInfluentialCariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
“related complications, but not cardiovascular events, increase with increasing liver fibrosis stages.(5)”
BackgroundKohli, D. R., Mettman, D. J., Andraws, N., Haer, E., Porter, J., Ulusurac, O., Ullery, S., Desai, M., Siddiqui, M. S., & Sharma, P. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2022.08.035 · Cited by 53
Armandi, A., Sanavia, T., Younes, R., Caviglia, G. P., Rosso, C., Govaere, O., Liguori, A., Francione, P., Gallego‐Durán, R., Ampuero, J., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-330815 · Cited by 56
Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
Mantovani, A., Lonardo, A., Stefan, N., & Targher, G. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156014 · Cited by 59
Schwimmer, J. B., Thai, N. Q. N., Noon, S. L., Ugalde‐Nicalo, P., Anderson, S. R., Chun, L. F., David, R. S., Goyal, N. P., Newton, K. P., Hansen, E. G., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001357 · Cited by 61
Self-citationIncidence of liver cancer in young adults according to the Global Burden of Disease database 2019
Danpanichkul, P., Aboona, M. B., Sukphutanan, B., Kongarin, S., Duangsonk, K., Ng, C. H., Muthiah, M. D., Huang, D. Q., Seko, Y., Díaz, L. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000872 · Cited by 59
“[ 35 ] Regarding primary liver cancer from alcohol, given that only a small percentage of individuals who consume alcohol develop liver cancer in young adulthood, screening for liver cancer may not be highly cost-effective.”
Li, Y., Zhang, T., Zhang, J., Liu, Q., Jia, Q., Chen, W., Tang, Q., Xiong, Y., Xia, Y., Xu, Y., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122232 · Cited by 52
Krishnan, A., Schneider, C. V., Hadi, Y. B., Mukherjee, D., Alshehri, B. Y., & Alqahtani, S. A. (2023) · Diabetologia · doi:10.1007/s00125-023-06057-5 · Cited by 57
“The presence of NAFLD increases the incidence of type 2 diabetes and accelerates the development of complications in type 2 diabetes [5].”
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 60
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
“12,15 Accordingly, EASL-EASD-EASO Clinical Practice Guidelines recommend that adults with non-cirrhotic MASH and > − stage F2 liver fi brosis should be considered for a MASH-targeted treatment with resmetirom, the fi rst FDA-approved treatment for MASH, whereas there are no recommended MASH-targeted…”
Canivet, C. M., Costentin, C., Irvine, K. M., Delamarre, A., Lannes, A., Sturm, N., Oberti, F., Patel, P. J., Decaens, T., Irles‐Depé, M., et al. (2023) · Hepatology · doi:10.1002/hep.32665 · Cited by 49
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
Gupta, H., Min, B.-H., Ganesan, R., Gebru, Y. A., Sharma, S. P., Park, E., Won, S., Jeong, J., Lee, S.-B., Cha, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030550 · Cited by 56
“Mortality and liver-associated complications start to become aggravating in the fibrosis stage in NAFLD patients [6].”
BackgroundMacrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications
Chi, Y., Jiang, H., Yin, Y., Zhou, X., Shao, Y., Li, Y., & Rao, J. (2025) · MedComm · doi:10.1002/mco2.70256 · Cited by 62
“Despite established correlations between fibrotic burden and clinical outcomes in MASLD [205], the fundamental mechanisms mediating disease advancement persist as unresolved scientific questions, creating critical barriers to developing effective antifibrotic MASH interventions [206].”
Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease
Ochoa‐Allemant, P., Hubbard, R. A., Kaplan, D. E., & Serper, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1809 · Cited by 63
Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity
Tong, L., Chen, Z., Li, Y., Wang, X., Yang, C., Li, Y., Zhu, Y., Lu, Y., Liu, Q., Xu, N., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.003 · Cited by 52
Owrangi, S., Paik, J. M., Golabi, P., de Avila, L., Hashida, R., Nader, A., Paik, A., Henry, L. L., & Younossi, Z. M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18451 · Cited by 61
Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease
David, N., Antignac, J., Roux, M., Marchand, P., Michalak, S., Oberti, F., Fouchard, I., Lannes, A., Blanchet, O., Calès, P., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108235 · Cited by 46
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 52
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD
Palomer, X., Wang, J.-R., Escalona, C., Wu, S., Wahli, W., & Vázquez‐Carrera, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.008 · Cited by 54
Chung, G. E., Jeong, S., Cho, E. J., Yoo, J., Cho, Y., Lee, K., Shin, D. W., Kim, Y. J., Yoon, J., Han, K., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155222 · Cited by 51
Vilar-Gomez, E., Vuppalanchi, R., Gawrieh, S., Samala, N., & Chalasani, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000023 · Cited by 42
“[1,2] Cardiovascular diseases (CVDs) and extrahepatic malignancies have been reported as the most common causes of mortality for patients with NAFLD.[3,4] However, liver-related deaths may significantly increase in a dose-dependent manner with increasing fibrosis stages; stages 3 or 4 of fibrosis may display the highe…”
BackgroundSelf-citationSiddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A., & Sanyal, A. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.018 · Cited by 42
Self-citationMoreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 55
Liver biopsy evaluation in MASH drug development: Think thrice, act wise
Harrison, S. A., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.008 · Cited by 53
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 52
Self-citationThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Extrahepatic morbidities and mortality of NAFLD : an umbrella review of meta‐analyses
Yi, M., Peng, W. J., Xi, F., Teng, F., Tang, Y., Kong, Q., & Chen, Z. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17165 · Cited by 48
Chalasani, N., Gómez, E. V., Loomba, R. S., Yates, K. P., Diehl, A. M., Neuschwander‐Tetri, B. A., Dasarathy, S., Kowdley, K. V., Terrault, N. A., Wilson, L., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000896 · Cited by 45
“[11,12] Furthermore, we found a significant and positive interaction between PNPLA3 and AF, as well as the risk of MALO.”
Self-citationMetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 62
“Despite their long-known similarities, MASLD and ALD have traditionally been considered two separate conditions.”
InfluentialAminian, A., Aljabri, A., Wang, S. Z., Bena, J., Allende, D. S., Rosen, H., Arnold, E., Wilson, R. L., Milinovich, A., Loomba, R. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03480-y · Cited by 56
Self-citationZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Gao, B., Arab, J. P., Liangpunsakul, S., Ding, W., Szabó, G., Mehal, W. Z., Wang, H., He, Y., Stärkel, P., Llorente, C., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100319 · Cited by 54
“Chronic alcohol consumption decreases bacterial diversity, reduces beneficial taxa Open access and promotes expansion of pathobionts like Enterococcus faecalis and Escherichia coli .”
Self-citationNAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.028 · Cited by 41
Pickhardt, P. J., Correale, L., & Hassan, C. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03800-9 · Cited by 67
“Nonetheless, moderate hepatic steatosis increases the risk for progression hepatic fibrosis [69], which is ultimately the factor that determines liver-specific mortality [70].”
BackgroundLee, J., Westphal, M., Vali, Y., Boursier, J., Petta, S., Ostroff, R. M., Alexander, L. E., Chen, Y., Fournier, C., Geier, A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000364 · Cited by 50
Noureddin, M., Mena, E., Vuppalanchi, R., Samala, N. R., Wong, M., Pacheco, F., Polanco, P., Sakkal, C., Antaramian, A., Chang, D. Y., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000055 · Cited by 41
“The improvements associated with Agile 3+ and Agile 4 are particularly important, as patients with ≥F3 and F4 are at the highest risk of developing clinical liver events and outcomes; these 2 groups were previously not sufficiently well ruled in using LSM by VCTE of FIB4.”
BackgroundValenzuela‐Vallejo, L., Guatibonza-García, V., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155248 · Cited by 44
Martínez‐Domínguez, S. J., García, S. G., Gargallo-Puyuelo, C. J., Llera, B. G., Callau, P., Mendi, C., Arroyo, M., Simón-Marco, M. Á., Ampuero, J., & Gomollón, F. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad175 · Cited by 45
Vilar-Gomez, E., Vuppalanchi, R., Gawrieh, S., Pike, F., Samala, N., & Chalasani, N. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002222 · Cited by 39
Self-citationYoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1993 · Cited by 43
Fujii, H., Suzuki, Y., Sawada, K., Tatsuta, M., Maeshiro, T., Tobita, H., Tsutsumi, T., Akahane, T., Hasebe, C., Kawanaka, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13947 · Cited by 42
Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression
Yan, T., Yan, N., Xia, Y., Sawaswong, V., Zhu, X., Dias, H. B., Aibara, D., Takahashi, S., Hamada, K., Saito, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci166731 · Cited by 49
“Growing clinical evidence revealed that liver fibrosis is a main determinant of outcomes or all-cause mortality in liver disease (1–6).”
BackgroundJohnson, P. J., Kalyuzhnyy, A., Boswell, E., & Toyoda, H. (2024) · BJC Reports · doi:10.1038/s44276-024-00050-0 · Cited by 45
“Our approach would be applicable to NAFLD where the pathway to, and frequency of, cirrhosis and HCC remains contentious [34 – 36].”
Method
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.